Abstract
Get full access to this article
View all access options for this article.
References
1.Orchard Therapeutics . Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (Atidarsagene Autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S. March 18, 2024 . Available from: https://ir.orchard-tx.com/news-releases/news-release-details/orchard-therapeutics-receives-fda-approval-lenmeldytm [Last accessed: March 19, 2024].
2.
Kansteiner
M.
Takeda Winds Down Manufacturing and R&D Operations in Austria after Gene Therapy Pivot, Plots 190 Layoffs . March 13, 2024. Available from: https://www.fiercepharma.com/pharma/following-gene-therapy-pivot-takeda-says-its-winding-down-manufacturing-and-rd-operations [Last accessed: March 16, 2024].
3.CRISPR Therapeutics . Prospectus Supplement , February 13, 2024. Available from: https://ir.crisprtx.com/static-files/3266040b-3f7a-47f0-830b-24c2e605d751 [Last accessed: March 11, 2024].
4.CRISPR Therapeutics . CRISPR Therapeutics Announces $280 Million Registered Direct Offering . February 13, 2024. Available from: https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-announces-280-million-registered-direct [Last accessed: March 11, 2024].
5.enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress . March 11, 2024. Available from: https://engene.com/engene-reports-first-quarter-2024-financial-results-and-recent-corporate-progress/ [Last accessed: March 11, 2023].
6.REGENXBIO . REGENXBIO Announces New Positive Initial Efficacy Data from AFFINITY Duchenne® Trial . March 5, 2024. Available from: https://regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-announces-new-positive-initial-efficacy-data-affinity [Last accessed: March 13, 2024].
7.Asgard Therapeutics . Asgard Therapeutics Announces €30 Million Series A Financing to Advance its First-in-Class In Vivo Cell Reprogramming Platform for Immuno-oncology . March 14, 2024. Available from: https://www.asgardthx.com/asgard-therapeutics-announces-e30-million-series-a-financing-to-advance-its-first-in-class-in-vivo-cell-reprogramming-platform-for-immuno-oncology/#_edn3 [Last accessed: March 16, 2024].